Breaking News

Kanvas Biosciences Raises $12.5M in Additional Funding

The capital will be used to further develop its spatial biology platform and advance two novel therapeutics in its Immuno-oncology Program.

Author Image

By: Charlie Sternberg

Associate Editor

Kanvas Biosciences, a full-stack spatial biology company, has raised $12.5 million in additional funding—bringing Kanvas’s total funding to $29.5 million. The funding will be used to further develop the company’s spatial biology platform and advance two novel therapeutics in its Immuno-oncology Program, KAN-001 and KAN-003 — KAN-001 to an Investigational New Drug (IND) filing in 2025. Kanvas Bioscience’s spatial biology platform provides the unique ability to map host-m...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters